论文部分内容阅读
防治增生性玻璃体视网膜病变(PVR)最直接有效的给药方式是玻璃体腔注射。游离药物在玻璃体腔的半衰期短,为维持药物的有效浓度,常需反复注射,给治疗带来诸多不变。为此近年来以药物的长效剂型防治 PVR 成为研究热点。本文介绍应用于玻璃体的抗 PVR 药物的各种缓释剂型,并分别评价其优缺点。它们各有所长,也均有不足。因此尚需进一步探索,以研究出释药时间长而速度恒定、生物相容性好、使用方便易消毒易保存的理想的药物长效剂型。
Prevention and treatment of proliferative vitreoretinopathy (PVR) the most direct and effective way of administration is intravitreal injection. Free drugs in the vitreous cavity of the short half-life, in order to maintain the effective concentration of drugs, often need repeated injections, to treat a lot of the same. In recent years, drug long-acting formulations to prevent and cure PVR has become a research hotspot. This article describes the various sustained release formulations of anti-PVR drugs for vitreous and their advantages and disadvantages, respectively. They have their own strengths and weaknesses. Therefore, further exploration is still needed to find out the ideal long-acting drug dosage form that has long-lasting drug release rate, good biocompatibility, easy to use, easy to disinfect and easy to store.